Lastly, the sclerosing pattern should be taken into account in patients with IgAN, similar to class VI LN, highlighting the need for more intensified nephroprotective measures (e.g., addition of SGLT2 inhibitors or the dual endothelin-angiotensin receptor blocker). This evidence concerns the gene SLC5A2 and lobular neoplasia.